Jury ruled J&J failed to warn about Risperdal’s gynecomastia risk
In a 10 out of 12 vote, a jury in Philadelphia asserted that Johnson & Johnson’s (J&J) Janssen Pharmaceuticals failed to warn patients and prescribers about the possible risk of gynecomastia among young males taking the atypical antipsychotic drug Risperdal, Market Watch reported on Friday, March 20.
The jury decision came after a three week trial over a case filed by a 19-year-old plaintiff who claimed that taking the antipsychotic drug from age six to ten led him to develop breasts, a condition know as gynecomastia. The company, however, concealed the risk from prescribers. According to the report, the patient stopped using the drug in 2006, the year when the U.S. Food and Drug Administration granted Risperdal approval for limited use in children and adolescents.
Since its FDA approval in 1993 and prior to 2006, Risperdal was only allowed for use in adults and was prescribed off-label to young patients.
If you believe Risperdal has caused your loved one to suffer from any adverse health condition, a lawyer at Williams Kherkher might be able to represent you in seeking justice and compensation. Call us at (800) 220-9341 to learn more about taking legal action today.